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Abstract
Preventing the emergence of ceftriaxone-resistant Neisseria gonorrhoeae can potentially avert 
hundreds of millions of dollars in direct medical costs of gonorrhea and gonorrhea-attributable 
HIV infections. In the illustrative scenario we examined, emerging ceftriaxone resistance could 
lead to 1.2 million additional N. gonorrhoeae infections within 10 years, costing $378.2 million.
Gonococcal resistance to treatment may increase gonorrhea incidence rates through factors 
such as increased duration of infection.1–3 One of the targets of the National Strategy for 
Combating Antibiotic-Resistant Bacteria is to maintain the prevalence of ceftriaxone 
resistance at less than 2% of Neisseria gonorrhoeae infections.4 Achieving this target could 
yield substantial health and economic benefits by preventing increases in the incidence of 
gonorrhea. To provide a plausible example of these potential benefits, we performed a 
modeling exercise of an illustrative scenario of increased gonorrhea incidence in the United 
States caused by emerging cephalosporin resistance. We focused on the potential benefits of 
preventing emerging resistance, not on the cost-effectiveness (costs and benefits) of 
activities to prevent emerging resistance.
We estimated the increased health and economic burden of ceftriaxone-resistant N. 
gonorrhoeae in a scenario in which the emergence of ceftriaxone resistance was assumed to 
have an impact on gonorrhea incidence consistent with the impact estimated for the 
emergence of ciprofloxacin resistance during the late 1990s and 2000s. In our approach, the 
gonorrhea incidence rate in a given year was calculated based on (1) the percentage of N. 
gonorrhoeae infections resistant to treatment in the given year and (2) the gonorrhea 
incidence rate in the previous year. To focus on the potential influence of antimicrobial 
resistance on gonorrhea incidence, we assumed that the national gonorrhea incidence rate 
would be constant over time in the absence of changes to the percentage of N. gonorrhoeae 
infections resistant to treatment. Specifically, we used the following equation:
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Gt = CONSTANT + β1Gt − 1 + β2Rt,
where Gt is the log of the gonorrhea incidence rate in year t and Rt is the percentage of N. 
gonorrhoeae infections resistant to treatment in year t. This equation is based on the 
regression equation that was used in a recent analysis of historical gonorrhea surveillance 
data and ciprofloxacin antimicrobial resistance data in the United States.1 The values 0.553 
and 0.71 were applied for β1 and β2 (Table 1), respectively, based the previous analysis from 
which we obtained the model equation.1 Although the original regression model included a 
range of demographic variables as well as city and year variables, in our application of the 
model, we assumed that these factors would be fixed over time and could be therefore be 
subsumed into the CONSTANT term. The CONSTANT term was assigned a value of 2.47 
so that our equation would yield a steady gonorrhea incidence rate over time in the scenario 
of no emerging resistance (see Appendix, http://links.lww.com/OLQ/A201).
We assumed that the annual number of N. gonorrhoeae infections (reported cases plus 
unreported infections) in the absence of emerging resistance would be 820,000 for the entire 
United States, based on a published estimate of annual incidence.5 The lower bound 
(395,000) reflects the approximate number of reported gonorrhea cases in 2015,10 and the 
upper bound (1,245,000) was calculated such that the base case would be the midpoint of the 
lower and upper bounds.
We estimated gonorrhea incidence during a 10-year period, for 2 scenarios. We assumed that 
prevalence of resistance would be at 2% of N. gonorrhoeae infections at the start of each 
scenario, for clarity and ease of interpretation of the results in terms of the benefits of 
maintaining prevalence of resistance at 2% or lower. In scenario 1, the prevalence of 
resistance was assumed to remain at 2% of N. gonorrhoeae infections and the annual 
incidence of N. gonorrhoeae infections was 820,000 for all years (year 1 through year 10). 
In scenario 2 (the “emerging resistance” scenario), the prevalence of resistance was assumed 
to increase linearly from 2% in year 0 to 15% in year 6 and remain at 15% through year 10. 
This assumption of the increase in resistance in years 1 to 6 is consistent with historical data 
on the emergence of fluoroquinolone-resistant N. gonorrhoeae in the 1990s.11
We calculated the costs of scenario 2 compared with scenario 1. We included the direct 
lifetime medical costs (2016 US dollars) of N. gonorrhoeae infections and gonorrhea-
attributable HIV infections. The discounted lifetime cost per gonococcal infection was $86 
for male individuals and $383 for female individuals. These lifetime cost estimates per 
infection account for the possibility that the infection might not be treated and include 
potential sequelae costs (Table 1).6 We assumed that male individuals account for 57% of N. 
gonorrhoeae infections.5 We also assumed that each N. gonorrhoeae infection would have a 
0.0005 probability of resulting in a gonorrhea-attributable HIV infection.8,9 We applied a 
lifetime cost per HIV infection of $351,000, which accounts for factors such as the average 
time from infection to initiation of treatment, the average CD4 count at diagnosis, and 
treatment uptake and cost.7
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We conducted 1-way sensitivity analyses in which the 7 key parameters listed in Table 1 
were varied one at a time, from their lower-bound value to their upper-bound value, while 
holding all other parameters at their base case values. The lower- and upper-bound values we 
applied are listed in the “range” column of Table 1. We also performed a probabilistic 
sensitivity analysis in which all 7 parameters were varied simultaneously. Specifically, we 
ran the model 10,000 times, each time selecting a random value for each of the 7 parameters 
(see Appendix, http://links.lww.com/OLQ/A201).
Compared with a scenario in which the prevalence of ceftriaxone resistance is maintained at 
2% of N. gonorrhoeae infections (scenario 1), gonorrhea rates in the scenario of emerging 
resistance (scenario 2) were estimated to be 2% higher in year 1, 14% higher in year 5, and 
22% higher in year 10. During a 10-year period, there would be a total of 1.2 million 
additional N. gonorrhoeae infections (at a cost of $207.7 million) and 579 gonorrhea-
attributable HIV infections (at a cost of $170.5 million), for a total cost of $378.2 million 
(Table 2).
In the 1-way sensitivity analyses, the cumulative number of additional N. gonorrhoeae 
infections within 10 years ranged from 250,300 to 1,879,300 and the cumulative, additional 
costs ranged from $81.9 million to $613.7 million (Table 3). The lower values were obtained 
when applying the lower-bound value of 5% for peak ceftriaxone resistance, and the higher 
values were obtained when applying the upper-bound value of the β2 parameter, which 
reflects the impact of resistance on gonorrhea incidence. The cumulative number of 
additional HIV infections ranged from 58 to 1157, when applying the lower- and upper-
bound values, respectively, of the probability of gonorrhea-attributable HIV infection. In the 
multiway probabilistic sensitivity analysis, the 5th and 95th percentiles of results of the 
10,000 simulations ranged from 172,300 to 2,558,000 for the cumulative number of 
additional N. gonorrhoeae infections, 20 to 2160 for the cumulative number of additional 
gonorrhea-attributable HIV infections, and $41 million to $1099 million for the cumulative 
additional costs (Table 3).
Substantial health and economic losses can be averted by maintaining the prevalence of 
ceftriaxone-resistant N. gonorrhoeae lower than 2%, particularly if ceftriaxone resistance 
emerges at a rate similar to the rate of ciprofloxacin resistance, if emerging resistance 
contributes to increased gonorrhea incidence, and if gonorrhea facilitates HIV acquisition 
and transmission to the extent that we assumed. The possibility of increased gonorrhea 
incidence due to emerging resistance has been illustrated by complex mathematical 
models2,3 as well as a recent ecological analysis of historical gonorrhea incidence and 
ciprofloxacin resistance data1 on which our model is based.
Our estimates are subject to considerable uncertainty. We illustrated the possible health and 
economic burden of emerging resistance in a scenario in which the impact of emerging 
cephalosporin resistance was assumed to be similar to the impact estimated for emerging 
ciprofloxacin resistance in the 1990s and 2000s. The main benefit of this simple approach is 
that we could estimate the cost and health effects of emerging cephalosporin resistance by 
using a published, ecological analysis of the association between emerging ciprofloxacin 
resistance and increased gonorrhea incidence. This approach precludes the need for a 
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dynamic transmission model and associated assumptions regarding the effect of 
cephalosporin resistance on factors such as treatment efficacy and duration of infection. The 
main limitation of this simple approach is that ciprofloxacin resistance and cephalosporin 
resistance might differ in many ways (including the rate at which resistance increases), and 
the potential effect of cephalosporin resistance on gonorrhea incidence rates might differ 
substantially from that of ciprofloxacin resistance.1,12 Even if ciprofloxacin resistance and 
cephalosporin resistance do not differ, our approach is based on data from the 1990s and 
does not account for changes in sexual risk behavior, testing frequencies, awareness of 
antimicrobial resistance, and other factors. Given this considerable uncertainty, we note that 
the health and economic burden of emerging resistance could be substantially higher or 
lower than suggested by the particular scenario we examined. Furthermore, because the 
lower- and upper-bound values we applied in the sensitivity analyses for an influential model 
parameter (the impact of resistance on gonorrhea incidence; β2) were based on the 
ciprofloxacin study, the range of results generated in our sensitivity analyses likely 
underestimates the true degree of uncertainty in the potential effects of emerging resistance. 
Another limitation is that the regression equation in the ciprofloxacin study on which our 
model is based included demographic and other factors, whereas we assumed that any 
influence of these factors on gonorrhea incidence rates would be constant over time and thus 
did not explicitly include these factors in our model.
Other model assumptions are subject to uncertainty as well, particularly the estimate of the 
probability of a gonorrhea-attributable HIV infection per N. gonorrhoeae infection. The 
estimate we applied is based on a simple and dated approximation,8 whereas a dynamic 
transmission model with both HIV and gonorrhea would be needed to generate more reliable 
estimates of the number of gonorrhea-attributable HIV infections. Furthermore, more 
information on the current effect of gonorrhea on HIV acquisition and transmission is 
needed, given that the probability of gonorrhea-attributable HIV infection may have 
decreased over time with the availability of antiretroviral therapy for those with HIV and 
preexposure prophylaxis for those at risk for acquiring HIV.13,14 For these reasons, we 
included in Table 2 the “cost of additional N. gonorrhoeae infections” and the “cost of 
additional gonorrhea-attributable HIV infections” so that readers can see these 2 cost 
components separately. We also note that we did not include the possibility that the average 
treatment cost per case of gonorrhea might increase over time in a scenario of emerging 
resistance, perhaps due to more intensive treatment regimens. Another important 
clarification is that our analysis is not a cost-effectiveness analysis, because we assessed 
only the benefits and not the costs of preventing the emerging of resistance. The costs to 
develop, implement, and maintain programs to keep the prevalence of ceftriaxone resistance 
at less than 2% of N. gonorrhoeae infections were not included in this study.
Despite these limitations, our model provides a useful illustration of the possible health and 
economic costs of ceftriaxone-resistant N. gonorrhoeae. Future studies could address the 
cost-effectiveness of efforts to prevent emerging resistance, which would require estimates 
of the costs and benefits of such activities. However, whatever the costs might be to combat 
antibiotic-resistant gonorrhea, our results illustrate the possibility that these costs can be 
offset, at least in part, by averting the costs of emerging resistance. Complex mathematical 
models of gonorrhea have been developed to help understand the development and spread of 
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antibiotic resistance, and these models can be valuable tools to inform strategies to combat 
resistance.2,15–17 Preventing the emergence of ceftriaxone-resistant N. gonorrhoeae in 
accordance with the National Strategy for Combating Antibiotic-Resistant Bacteria targets 
can potentially avert hundreds of millions of dollars in direct medical costs of gonorrhea and 
gonorrhea-attributable HIV infections.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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